Ruthenium anticancer compounds: Challenges and expectations

被引：216
作者：
Bratsos, Ioannis
Jedner, Stephanie
Gianferrara, Teresa
Alessio, Enzo
机构：
[1] Univ Trieste, Dipartimento Sci Chim, I-34127 Trieste, Italy
[2] Univ Trieste, Dipartimento Sci Farmaceut, I-34127 Trieste, Italy
来源：
CHIMIA | 2007年 / 61卷 / 11期
关键词：
anticancer; antimetastatic; dimethylsulfoxide; medicinal inorganic; chemistry ruthenium;
D O I：
10.2533/chimia.2007.692
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imiclazole) and [IndH] trans-[RuCl4(Ind)(2)] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms.
引用
收藏
页码：692 / 697
页数：6
相关论文
共 35 条
[21]   New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes [J].
Hotze, ACG ;
Bacac, M ;
Velders, AH ;
Jansen, BAJ ;
Kooijman, H ;
Spek, AL ;
Haasnoot, JG ;
Reedijk, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (09) :1743-1750
[22]  
Keppler B. K., 1993, METAL COMPLEXES CANC, P187
[23]   Clinical development of platinum complexes in cancer therapy: an historical perspective and an update [J].
Lebwohl, D ;
Canetta, R .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) :1522-1534
[24]  
Mestroni G, 1994, Met Based Drugs, V1, P41
[25]   A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent [J].
Rademaker-Lakhai, JM ;
van den Bongard, D ;
Pluim, D ;
Beijnen, JH ;
Schellens, JHM .
CLINICAL CANCER RESEARCH, 2004, 10 (11) :3717-3727
[26]   New insights into the redox chemistry of ruthenium metallopharmaceuticals:: The electrochemical behaviour of [LH][trans-RuIIICl4L2] (L = imidazole or indazole) complexes [J].
Ravera, M ;
Cassino, C ;
Baracco, S ;
Osella, D .
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (04) :740-746
[27]   Using coordination chemistry to design new medicines [J].
Ronconi, Luca ;
Sadler, Peter J. .
COORDINATION CHEMISTRY REVIEWS, 2007, 251 (13-14) :1633-1648
[28]   Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A [J].
Sava, G ;
Bergamo, A ;
Zorzet, S ;
Gava, B ;
Casarsa, C ;
Cocchietto, M ;
Furlani, A ;
Scarcia, V ;
Serli, B ;
Iengo, E ;
Alessio, E ;
Mestroni, G .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) :427-435
[29]   Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP [J].
Schluga, P ;
Hartinger, CG ;
Egger, A ;
Reisner, E ;
Galanski, M ;
Jakupec, MA ;
Keppler, BK .
DALTON TRANSACTIONS, 2006, (14) :1796-1802
[30]   Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis(2-phenylazopyridine)ruthenium(II) complexes [J].
Velders, AH ;
Kooijman, H ;
Spek, AL ;
Haasnoot, JG ;
de Vos, D ;
Reedijk, J .
INORGANIC CHEMISTRY, 2000, 39 (14) :2966-+
1234